Cell Biotech Co., Ltd · KRX:049960
Cell Biotech — Q3 2025 Earnings Presentation
8 slides from Cell Biotech's earnings presentation, November 2025
Slide 1: CELL BIOTECH 2025 3Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2025 3Q Earnings Release 2025. 11. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual result
Slide 2: Revenue up 26.3% to KRW 15.4 billion, operating profit up 6.3%
CELL BIOTECH Revenue up 26.3% to KRW 15.4 billion, operating profit up 6.3% to KRW 2.2 billion Domestic revenue up 15.6%, overseas revenue up 34.2% Duolac brand sales up 23.7% to KRW 6.8 billion, OEM/ODM sales up 32.6% to KRW 7.3 billion, Raw material sales up 6.3% to KRW 1.2 billion (unit : KRW 100
Slide 3: Quarterly revenue and full year revenue
CELL BIOTECH 3q revenue KRW 15.3 billion, yoy +26.3%, qoq +28.9% Quarterly revenue Full year revenue (unit : KRW mil) (unit : KRW mil) 3
Slide 4: Quarterly profit and full year profit
CELL BIOTECH 3q operating profit KRW 2.2 billion, yoy +6.1% Net Profit KRW +3.4 bil. Quarterly profit Full year profit (unit : KRW mil) 4
Slide 5: 3Q revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH 3q revenue of Duolac brand +23.7% to 6.9 KRW bil., OEM/ODM +32.6% to 7.3 KRW bil., and raw material +6.3% to 1.2 KRW bil. (unit : KRW mil) 5
Slide 6: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 12 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world clinical phase 1 IND submitted (Mar 5, 2021) for 12 consecutive years 2) Acquisition European patent of
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria secured 2) Cellbiotech, Probiotics Leading... Global Leap FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2024 3q 2025 3q 2024 .12 2025 3q Amount Ratio Amount Ratio Assets 1,304 1,346 Revenue 121.6 100.0 153.6 100.0 Current Assets 971.48 1,011 Gross profit 86.7 71.3 110.3 71.9 Non current Asse